He Yaling, Li Yuqian, Zhai Zhihan, Liu Pengling, Nie Luting, Zheng Yiquan, Hou Jian, Huo Wenqian, Mao Zhenxing, Zhang Zhenzhong, Wang Chongjian, Liu Xiaotian
Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.
Exp Ther Med. 2022 Sep 5;24(5):652. doi: 10.3892/etm.2022.11589. eCollection 2022 Nov.
There are increasing numbers of studies investigating the potential link between microRNAs (miRNAs) and type 2 diabetes mellitus (T2DM) risk. Based on the prior evidence and the differentially expressed candidate plasma exosome miRNAs in our established discovery study, the current meta-analysis studied miR-126 and miR-122 specifically. The purpose of the present study was to systematically and quantitatively evaluate the relationship of miR-126 and miR-22 expression level with T2DM risk as well as related glucose metabolism parameters. Moreover, the present study was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline (PRISMA 2020 statement). PubMed, Embase, Web of Science, Cochrane and Chinese National Knowledge Infrastructure electronic databases were used to identify eligible original studies prior to May 3, 2022. The random-effects models were employed to explore the overall effect estimates [odds ratio (OR) and 95% confidence interval (CI), or correlation coefficient (r, 95% CI)]. The subgroup analyses were conducted to examine the potential sources of heterogeneity. The potential publication bias was assessed by the Begg's funnel plot and Egger's tests. A total of 46 articles were included in the present meta-analysis. The results revealed that higher exposure level of miR-126 was related to lower T2DM risk in 5 analytical epidemiological studies [OR=0.73, 95% CI: (0.55, 0.96)], lower fasting blood glucose (FBG) [N=22, r=-0.26, 95% CI: (-0.42, -0.10)], and lower homeostasis model assessment of insulin resistance (HOMA-IR) index [N=9, r=-0.28, 95% CI: (-0.52, -0.05)]. Besides, positive correlations were observed between miR-122 expression and FBG [N=10, r=0.34, 95% CI: (0.20, 0.48)], as well as HOMA-IR index [N=9, r=0.40, 95% CI: (0.16, 0.64)]. The relationship of miR-126 and miR-122 expression with T2DM risk and these glucose metabolism parameters may be influenced by study types, sample size, different source and mean age of participants. In conclusion, in the general healthy population, higher miR-126 expression was related to lower T2DM risk, FBG level and HOMA-IR index; higher miR-122 expression was closely correlated with higher FBG level and HOMA-IR index. These findings have notable clinical and public health implications for screening and control glucose metabolic disorders, insulin resistance and T2DM development.
越来越多的研究在探究微小RNA(miRNA)与2型糖尿病(T2DM)风险之间的潜在联系。基于先前的证据以及我们已开展的探索性研究中差异表达的候选血浆外泌体miRNA,本荟萃分析专门研究了miR-126和miR-122。本研究的目的是系统且定量地评估miR-126和miR-22表达水平与T2DM风险以及相关糖代谢参数之间的关系。此外,本研究是依据系统评价和荟萃分析的首选报告项目指南(PRISMA 2020声明)进行的。在2022年5月3日之前,使用PubMed、Embase、Web of Science、Cochrane和中国知网电子数据库来识别符合条件的原始研究。采用随机效应模型来探索总体效应估计值[比值比(OR)和95%置信区间(CI),或相关系数(r,95%CI)]。进行亚组分析以检查异质性的潜在来源。通过Begg漏斗图和Egger检验评估潜在的发表偏倚。本荟萃分析共纳入46篇文章。结果显示,在5项分析性流行病学研究中,较高的miR-12